Crinetics pharmaceuticals, inc. (CRNX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Grant revenues

71

321

505

0

367

781

548

657

442

528

640

832

45

Operating expenses:
Research and development

13,862

12,143

11,823

10,285

7,255

7,651

6,886

5,222

4,720

2,562

2,523

2,083

2,065

General and administrative

3,991

3,392

3,911

3,060

3,156

2,561

1,732

1,118

1,248

467

491

392

589

Total operating expenses

17,853

15,535

15,734

13,345

10,411

10,212

8,618

6,340

5,968

3,029

3,014

2,475

2,654

Loss from operations

-17,782

-15,214

-15,229

-13,345

-10,044

-9,431

-8,070

-5,683

-5,526

-

-2,374

-1,643

-

Other income (expense):
Interest income

556

655

835

960

1,010

999

534

151

64

-

6

7

-

Interest expense

-

-

-

-

-

-

-

-

-

-

2

3

-

Other income (expense), net

-134

-

-36

-42

18

-

-52

-36

-2

-

-12

-9

-

Total other income (expense), net

422

665

799

918

1,028

936

482

115

62

-

-8

-5

-

Net loss

-17,360

-14,549

-14,430

-12,427

-9,016

-8,495

-7,588

-5,568

-5,464

-2,521

-2,382

-1,648

-2,606

Other comprehensive income:
Unrealized gain on investment securities

19

-50

-36

89

84

-

-

-

-

-

-

-

-

Comprehensive loss

-17,341

-14,599

-14,466

-12,338

-8,932

-8,434

-7,588

-5,568

-5,464

-

-

-

-

Net loss per share:
Net loss per share – basic and diluted

-0.71

-0.60

-0.60

-0.51

-0.37

-0.35

-0.38

-2.41

-2.92

-1.68

-1.67

-1.22

-2.18

Weighted average shares outstanding – basic and diluted

24,488

24,236

24,208

24,161

24,095

24,375

20,016

2,307

1,870

-

1,430

1,348

-